Citigroup
TBPH icon

Citigroup’s Theravance Biopharma TBPH Stock Holding History

Citigroup’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353K Buy
21,747
+7,986
+58% +$141K ﹤0.01% 3727
2025
Q4 		$257K Buy
13,761
+5,678
+70% +$94.2K ﹤0.01% 3879
2025
Q3 		$118K Sell
8,083
-9,529
-54% -$120K ﹤0.01% 4200
2025
Q2 		$194K Sell
17,612
-12,150
-41% -$118K ﹤0.01% 4083
2025
Q1 		$266K Sell
29,762
-2,684
-8% -$25K ﹤0.01% 4028
2024
Q4 		$305K Buy
32,446
+3,357
+12% +$30.5K ﹤0.01% 4136
2024
Q3 		$234K Buy
29,089
+14,201
+95% +$123K ﹤0.01% 4236
2024
Q2 		$126K Sell
14,888
-10,719
-42% -$96.7K ﹤0.01% 4103
2024
Q1 		$230K Buy
25,607
+10,867
+74% +$101K ﹤0.01% 3949
2023
Q4 		$166K Buy
14,740
+9,161
+164% +$92.2K ﹤0.01% 3999
2023
Q3 		$48.1K Sell
5,579
-19,054
-77% -$184K ﹤0.01% 4158
2023
Q2 		$255K Buy
24,633
+17,585
+250% +$194K ﹤0.01% 3773
2023
Q1 		$76.5K Sell
7,048
-971
-12% -$10.3K ﹤0.01% 4122
2022
Q4 		$90K Sell
8,019
-3,647
-31% -$38.3K ﹤0.01% 4068
2022
Q3 		$118K Sell
11,666
-6,234
-35% -$58.4K ﹤0.01% 4015
2022
Q2 		$162K Sell
17,900
-2,692
-13% -$24.8K ﹤0.01% 3962
2022
Q1 		$197K Buy
20,592
+119
+0.6% +$1.17K ﹤0.01% 4090
2021
Q4 		$226K Sell
20,473
-16,117
-44% -$140K ﹤0.01% 4293
2021
Q3 		$271K Buy
36,590
+26,685
+269% +$298K ﹤0.01% 3962
2021
Q2 		$144K Buy
9,905
+3,626
+58% +$68.1K ﹤0.01% 4381
2021
Q1 		$128K Sell
6,279
-14,589
-70% -$277K ﹤0.01% 4249
2020
Q4 		$371K Buy
20,868
+11,195
+116% +$201K ﹤0.01% 4471
2020
Q3 		$143K Sell
9,673
-29,302
-75% -$549K ﹤0.01% 4849
2020
Q2 		$819K Buy
38,975
+20,300
+109% +$521K ﹤0.01% 3772
2020
Q1 		$432K Buy
18,675
+4,951
+36% +$124K ﹤0.01% 4006
2019
Q4 		$356K Buy
13,724
+6,595
+93% +$128K ﹤0.01% 4717
2019
Q3 		$138K Sell
7,129
-7,051
-50% -$142K ﹤0.01% 5450
2019
Q2 		$231K Buy
14,180
+1,576
+13% +$31.9K ﹤0.01% 5131
2019
Q1 		$285K Buy
12,604
+6,123
+94% +$155K ﹤0.01% 4753
2018
Q4 		$166K Buy
6,481
+4,673
+258% +$126K ﹤0.01% 5209
2018
Q3 		$59K Buy
1,808
+1,432
+381% +$39K ﹤0.01% 6382
2018
Q2 		$9K Buy
376
+158
+72% +$3.75K ﹤0.01% 7229
2018
Q1 		$5K Sell
218
-140
-39% -$3.85K ﹤0.01% 7215
2017
Q4 		$10K Sell
358
-9,334
-96% -$276K ﹤0.01% 7053
2017
Q3 		$332K Buy
9,692
+9,502
+5,001% +$311K ﹤0.01% 4530
2017
Q2 		$8K Sell
190
-65,301
-100% -$2.51M ﹤0.01% 6609
2017
Q1 		$2.41M Buy
65,491
+46,906
+252% +$1.5M ﹤0.01% 2294
2016
Q4 		$593K Buy
18,585
+12,692
+215% +$394K ﹤0.01% 4202
2016
Q3 		$213K Sell
5,893
-982
-14% -$27.3K ﹤0.01% 4597
2016
Q2 		$156K Sell
6,875
-13,567
-66% -$293K ﹤0.01% 4715
2016
Q1 		$384K Buy
20,442
+9,581
+88% +$157K ﹤0.01% 4430
2015
Q4 		$178K Buy
10,861
+10,857
+271,425% +$172K ﹤0.01% 4854
2015
Q3 		$0 Sell
4
-5,401
-100% -$68.8K ﹤0.01% 7703
2015
Q2 		$70K Sell
5,405
-1,462
-21% -$22.7K ﹤0.01% 5271
2015
Q1 		$120K Sell
6,867
-6,933
-50% -$127K ﹤0.01% 4883
2014
Q4 		$206K Buy
13,800
+11,975
+656% +$209K ﹤0.01% 4661
2014
Q3 		$42K Buy
1,825
+255
+16% +$7.4K ﹤0.01% 5433
2014
Q2 		$50K Buy
+1,570
New +$47.3K ﹤0.01% 5177

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's TBPH Position: Q1 2026 in Review

Citigroup increased its Theravance Biopharma (TBPH) stake by 58% in Q1 2026, buying an estimated $141K and bringing the position to 21,747 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Citigroup first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $2.41M in Q1 2017. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Citigroup held 21,747 shares of Theravance Biopharma worth $353K as of Q1 2026.
  • Citigroup bought 7,986 Theravance Biopharma shares in Q1 2026, an estimated $141K.
  • Theravance Biopharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3727 holding.
  • Citigroup first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
  • Citigroup's Theravance Biopharma position peaked at $2.41M in Q1 2017.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.